Non-replicating virus-derived particles and uses thereof
AssigneeCelverum Inc.
InventorsDavid Conrad, Cory Batenchuk, Fabrice Leboeuf, John Cameron Bell
Life of this patent
Estimating the term…
Abstract
There is described herein a non-replicating Rhabdovirus-derived particle that lacks the ability to spread between cells while having tropism against immortalized cells. The non-replicating Rhabdovirus-derived particle may have cytolytic tropism against immortalized cells. There is also described a non-replicating Rhabdovirus-derived particle that lacks the ability to spread between cells but has innate and/or adaptive immune-stimulating properties.
Claims7
A composition comprising a non-replicating, cell-internalizing Rhabdovirus-derived particle, wherein said Rhabdovirus-derived particle exhibits RNA which is cross-linked or cleaved into at least two discontinuous RNA polynucleotide sequences, and wherein the composition is produced from a 50 μl sample of 1×1010 plaque forming units per ml (PFU/ml) live Rhabdovirus subjected to a UV dose of 250 mJ/cm2 for about 40 seconds, the composition inducing less than 40% viability of immortalized cells and about 80% viability of normal non-cancer cells in an in-vitro cytotoxicity assay using a multiplicity of infection of 100 particles per cell.
An intravenous composition comprising a non-replicating, cell internalizing Rhabdovirus-derived particle for treating leukemia in a subject in need thereof, wherein said Rhabdovirus-derived particle exhibits RNA which is cross-linked or cleaved into at least two discontinuous RNA polynucleotide sequences, wherein the composition is produced from a 50 μl sample of 1×1010 plaque forming units per ml (PFU/ml) of live Rhabdovirus subjected to a UV dose of 250 mJ/cm2 for about 40 seconds, the composition inducing less than 40% viability of immortalized Vero cells and about 80% viability of normal neonatal human dermal fibroblasts, in an in vitro cytotoxicity assay using a multiplicity of infection of 100 particles per cell and wherein the composition induces immunogenic apoptosis upon in-vivo administration to a subject.
Dependencies are inferred from the claim text.